TherapeutAix Roundup: 2023

As 2023 comes to an end we wanted to take the time to reflect upon the year and share what we have been up to. From supporting our clients, participating in scientific meetings, and facilitating workshops to refreshing our website, it has been a busy year for the team at TherapeutAix.

Our clients and their projects have been keeping us most busy, and the infographic below shows the scope of this work. And beyond that: here are some more of our other highlights:

Website refresh

This year we decided it was time to update our website and give it a fresh feel, while highlighting our services and expertise. We added some dynamic text to our homepage and created two brand new pages.

The Our Story page explains how TherapeutAix came to be and the origin of our name and logo. It also gives an insight into the way we work and why creating this company was so important to the team.

We also created our Testimonials page as a way to share the feedback we have received from our clients and to showcase the different projects we are involved in.


This year we attended SMR meetings in both July and December and the ERS International Congress in September.

The SMR meetings involved presentations highlighting recent clinical candidates across therapeutic areas including cancer, immune disease and more, with a variety of targeting modalities. Included was also the presentation of the 2023 SMR award for Innovation and Impact in Medicines to the UK Vaccine Taskforce in recognition of those involved in the development approval and delivery of Covid vaccines.

The ERS International Congress took place in Milan, Italy and brought together the world’s respiratory experts to showcase the latest advances in respiratory medicine and science. TherapeutAix’s Simon Cruwys and Bob Humphries attended the event, which followed the theme of ‘Pollution, climate change and sustainable developments’ and highlighted the importance of having good environmental policies in place to support public health. We were intrigued by lots of good science, and lots of news (good and bad) specifically for drug candidates for idiopathic pulmonary fibrosis. We‘ll be commenting on that soon, so stay tuned!

Exciting developments for inhaled lung fibrosis therapies

Last year we made a series of posts highlighting the opportunities and challenges of developing inhaled therapies for idiopathic pulmonary fibrosis (IPF). This year we provided an update on the most recent developments in inhaled IPF therapies, which can be found in our blog here.

Progress is being made in clinical evaluation of both inhaled pirfenidone (AP01) and inhaled nintedanib (AP02), which is a promising development. The inhaled route offers the advantage of delivering a medicine directly to where it is needed – the lung – to bring benefit in IPF, while avoiding the limitations of systemic sideeffects associated with oral administration.

Our 2020 review article in Drug Discovery Today on “Drug Discovery and Development in IPF” is being updated to cover the ever-changing landscape in this field.  Look out for its publication in early 2024!


Workshops continue to be an important tool in our box. This past year, we held several events bringing together project teams, constructive challenge, and an external view. In addition to being of great value for or clients, these are fun to do – and it helps that we‘re continue to get excellent feedback!

Project Management Service

This year we also chose to highlight our project management service, where we provide oversight and co-ordinate activities of providers from within and outside our network to ensure timely and efficient provision of fit for purpose data.

At TherapeutAix we believe that, by bringing contributors together for regular meetings, we can generate a value that is greater than the sum of its parts. As part of our project management service we work with and support the internal project team leader with everything they need to ensure the project goes smoothly, from co-ordinating the activities of suppliers to providing creative ways to keep a project on track when dealing with unanticipated findings.

Our 2023 metrics

TherapeutAix roundup 2023 metrics


Looking ahead to 2024

The TherapeutAix team is looking forward to the new year and the new challenges and opportunities it will bring us. We are hoping that the year includes more developments in drug discovery as we continue to help bring molecules with promise to life.

If you would like to arrange a meeting or find out more about how we can help with your projects, please don’t hesitate to get in touch with us.

We would like to say a huge thank you to our clients and contacts for the trust and support you have shown us throughout the year. We wish you a happy and healthy 2024!


We’d like to send you our company updates, invites to events and any other relevant news. By providing your details and subscribing to this list, you are giving us your consent to send you these updates.

We’ll always be mindful of how often we send our updates and you can amend your preferences at any time.

We’ll never sell or swap your data with any organisation and we’ll store your details securely, respecting your trust and privacy. Please view our privacy policy for further details.

Marketing Permissions
Please select all the ways you would like to hear from TherapeutAix:
You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website.